Swiss biomaterials company Seprify has moved its cellulose platform from pilot testing to industrial-scale supply. The shift allows manufacturers to move beyond trials into regular sourcing and longer-term contracts.
The company raised €13.4 million in Series A funding to support the transition. Investors include Inter IKEA Group, Una Terra Early Growth Fund, Zürcher Kantonalbank, Cambridge Enterprise Ventures and Kickfund.
Seprify’s cellulose-based ingredients serve as alternatives to high-emission materials like titanium dioxide. The platform has been validated through partnerships with industry players and is now moving through supplier qualification and early commercial contracts. Target markets include cosmetics, personal care, food, pet food and coatings.
The company is working with more than 100 customer organizations at various stages, from active testing to early commercial supply.
“Our immediate priority is delivering consistent quality and reliable supply, meeting the operational standards large industrial customers require,” said Lukas Schertel, Co-founder and CEO of Seprify.
The new funding will help scale commercial production to hundreds of tonnes annually through manufacturing partners. It will also support commercial rollout and advance engineering for future industrial capacity.
“We look for solutions that can realistically replace high-impact incumbent materials while fitting into existing manufacturing and recycling systems,” said Robert Carleke, Innovation Ventures Manager at Inter IKEA Group. “Seprify’s cellulose platform has reached a level of maturity that makes this a credible path to explore.”
Seprify’s product lineup includes SilvaLuma, an SPF booster for cosmetics, and SilvaAlba, a food-grade whitening solution designed as an alternative to titanium dioxide.
The company combines process expertise, application knowledge and intellectual property covering manufacturing, products and end-use applications.
The post Seprify raises €13.4M to scale bio-based ingredients appeared first on World Bio Market Insights.
